A B S T R A C T Chediak-Higashi (CH) syndrome is a genetic disorder of children and certain animal species including the beige mouse. We have previously described a membrane abnormality in CH mouse polymorphonuclear leukocytes (PMN). Whereas normal mouse PMN do not form surface caps with concanavalin A except after treatment with agents such as colchicine that inhibit microtubule assembly, CH mouse PMN show spontaneous cap formation. This capping is inhibited by 3',5' cyclic guanosine monophosphate and by the cholinergic agonists carbamylcholine and carbamyl P-methylcholine that increase 3',5' cyclic guanosine monophosphate generation. These data suggested that microtubule function may be impaired in CH syndrome perhaps secondary to an abnormality in 3',5' cyclic guanosine monophosphate generation. The cholinergic agonists were also shown to prevent development of the giant granules that are pathognomonic of CH syndrome in embryonic fibroblasts isolated from CH mice and cultured in vitro.
A B S T R A C T Chediak-Higashi (CH) syndrome is a genetic disorder of children and certain animal species including the beige mouse. We have previously described a membrane abnormality in CH mouse polymorphonuclear leukocytes (PMN). Whereas normal mouse PMN do not form surface caps with concanavalin A except after treatment with agents such as colchicine that inhibit microtubule assembly, CH mouse PMN show spontaneous cap formation. This capping is inhibited by 3',5' cyclic guanosine monophosphate and by the cholinergic agonists carbamylcholine and carbamyl P-methylcholine that increase 3',5' cyclic guanosine monophosphate generation. These data suggested that microtubule function may be impaired in CH syndrome perhaps secondary to an abnormality in 3',5' cyclic guanosine monophosphate generation. The cholinergic agonists were also shown to prevent development of the giant granules that are pathognomonic of CH syndrome in embryonic fibroblasts isolated from CH mice and cultured in vitro.
In this report it is shown that an extreme degree of spontaneous concanavalin A cap formation is also characteristic of peripheral blood PMN from two patients with CH syndrome. This indicates an abnormality of microtubule function in CH syndrome in man. 3',5' cyclic guanosine monophosphate, carbamylcholine, and carbamyl f-methylcholine reduce spontaneous capping in CH cells. In addition, it is shown that monocytes isolated from the patients' blood and incubated in tissue culture generate a large complement of abnormal gran-
INTRODUCTION
The beige mouse, a spontaneous mutant of the C57 black mouse, is considered a homologue of Chediak-Higashi (CH) 1 syndrome of man (1) (2) (3) .
We recently described an abnormality of concanavalin A (Con A) distribution on polymorphonuclear leukocytes (PMN) from CH mice that suggested a defect in microtubule assembly in these cells (4) . In lymphocytes (5) , virus-transformed 3T3 fibroblasts (SV3T3) (6) and other cells, the disassembly of microtubules by treatment with agents such as colchicine and vinblastine that interact with microtubules (7) , favors the aggregation of Con A into a surface cap (reviewed in 8) . Con- sistent with this, PMN from normal black mice showed a random surface distribution of Con A except after incubation with colchicine which permits cap formation. By contrast, Con A was capped spontaneously on PMN from the beige or CH mouse to the same degree as on colchicine-treated normal cells. In addition, it was found that cyclic 3',5' guanosine monophosphate (cGMP) and the cholinergic agonists carbamylcholine (carbachol) and carbamyl P-methylcholine (bethanechol) that are capable of increasing cellular cGMP levels (9) Further studies showed that the continued presence of cholinergic agonists could also prevent generation of abnormal lysosomal granules in CH fibroblasts. Primary embryonic fibroblasts isolated from CH mice and maintained in tissue culture in the absence of drugs, developed the giant granules that are characteristic of CH syndrome in more than 60% of cells at confluency. However, when CH fibroblasts were plated at low cell density and maintained to confluence (10-14 days) in medium supplemented with carbachol (10 tM) only 9% of cells contained one or more giant granules (12) .
We report here the extension to man of these in vitro observations in mouse and indicate the potential therapeutic value of cholinergic agonists by studies of mice in vivo.
METHODS
The patients with the CH syndrome were 5 and 32 yr old males, the former brought to our attention by Dr. Thomas Stossel and the latter by Dr. George Buchanan, both of Children's Hospital Medical Center, Boston, Mass.
We were able to study the child's leukocytes through the cooperation of his personal physician, Dr. William Collins, New Bedford, Mass., his consulting hematologist, Dr. George Buchanan, and Dr. Stossel. For some studies, the personnel in the Department of Pathology, St. Luke's Hospital, New Bedford, Mass., obtained blood samples from the patient and allowed us use of their facilities for cell separation procedures. Signed informed consent was obtained from the patient's parents before studies were begun. The patient was in the accelerated phase of the disease and was being treated with alternate day corticosteroids (10-60 mg prednisone q.o.d.). Blood was obtained just before a scheduled dose of prednisone or on the alternate nontreatment day and only at a time when the patient's blood was drawn for studies necessary to the clinical management of his disease. The second patient has photophobia, pale irides, marked horizontal nystagmus, and a peripheral neuropathy. Giant granules were readily apparent in Wright stained preparations of peripheral blood leukocytes from both patients.
Peripheral blood mononuclear leukocytes from human subjects were obtained by means of Hypaque-Ficoll gradients (13) and resuspended in phosphate buffered saline (PBS). In some experiments the fractions were stored on ice for 3 h (during transportation) before use. Alternatively, whole blood was stored on ice, and the cells were isolated within 3 h in our laboratory. No (14, 15) . The use of acridine dyes for characterization of leukocyte lysosomal granules, including those in CH leukocytes, has been established by previous investigators (15, 16) .
The distribution of Con A on human PMN was observed by a modification of the method used previously (4) for mouse PMN. Portions (0.5 ml) of the cell suspensions were incubated in 2-ml plastic tubes at 37°C in the presence of 5 ,cg/ml fluorescein isothiocyanate conjugated Con A (FI-TC-Con A) for 5 min. 0.5 ml 2% paraformaldehyde was added to fix the cells during a further 5-10-min incubation at room temperature, after which the labeled cells were collected by centrifugation, washed once with PBS, and resuspended in 20-50 Al PBS. 10-iu portions were sealed under glass cover slips, and the distribution of fluorescence was observed by combined phase-fluorescence using a Zeiss Universal fluorescence microscope equipped as above but using a X 100 neofluar phase objective. 100 PMN were identified by phase-contrast microscopy and scored for the presence or absence of surface caps. The distribution of Con A was classified into three categories: A cell was considered (a) capped when all of the fluorescence was present in a knob or projection at one pole of the cell; (b) random, when fluorescence was seen as a discrete ring around the cell periphery, and (c) patched, when fluorescence was distributed in intracellular vesicles either around the cell periphery, under a capped area of the cell surface, or in aggregates near the center of the cell. Intracellular Con A was identified by its resistance to removal by postincubation of cells with the competing hapten sugar, a-methyl-D-mannoside.
All Con A could be eluted with the competing sugar from randomly-labeled and capped cells.
The distribution of Con A on mouse PMN was observed using cell monolayers as previously described (4) . Monolayers formed during a 30-min incubation of mouse peripheral blood leukocytes on glass cover slips followed by vigorous rinsing in PBS contained 80-85% PMN and 15-20% mononuclear cells. These cells were labeled with FITC-Con A (5 ,ug/ml) for 10 min, rinsed, wet mounted, and examined by combined phase-fluorescence microscopy as described above. The same monolayer technique was used for initial experiments with human PMN.
In Vivo experiments. In initial studies, two normal black RESULTS Distribution of Con A on human PMN. In experiments with the first patient the distribution of FITCCon A on CH PMN was compared with the distribution on normal human PMN using cell monolayers formed on glass cover slips at 37°C as previously used for mouse PMN (4) . In experiments with the second patient the distribution of FITC-Con A was determined using the new suspension assay described above. The results were qualitatively similar, but the suspension assay was found to be considerably more suitable than the monolayer assay for human cells.
Monolayers The results obtained when control PMN and PMN from the second patient were labeled using the suspension assay are shown in Table I . In normal preparations only 6% of cells formed caps with Con A, and the majority of cells showed a completely random distribution of fluorescence, as illustrated in Fig. 1A . Colchicine caused a dramatic increase in capping to 82% of cells (Fig. 1B) . CH PMN formed caps spontaneously on 75% of cells (Fig. IC) , and no further increase followed colchicine treatment. Spontaneous capping was restricted to PMN and was not observed on lymphocytes or monocytes present in the cell suspensions. Colchicineinduced capping on lymphocytes but not monocytes was observed in both normal and CH human cells. In both colchicine-treated normal PMN and untreated CH PMN, cGMP and cholinergic agonists, in the presence of imidazole to inhibit phosphodiesterase activity, reduced capping (Fig. 1 D) (17) . Fig. 2A cells from the first CH patient, an average of 68% of cells contained giant granules after incubation for 6 days in medium alone. However, cells cultured in the presence of 10 In vivo studies. Granule morphology of peripheral blood leukocytes isolated from carbachol or bethanecholtreated CH mice was dramatically different from granule morphology in untreated CH mouse PMN. In leukocytes from CH mice (80% PMN, 20% lymphocytes and monocytes) giant granules were apparent in most cells (compare the granules in normal cells, Fig. 3A with those in CH cells, Fig. 3B ). By contrast, very few giant granules were present in leukocytes from two carbacholtreated mice (5 Ag twice daily subcutaneously). Bethanechol (10 ug twice daily subcutaneously) also normalized leukocyte granule morphology in two mice (Fig.  3C ). In addition, oral administration of bethanechol (400 /g/ml ad lib.) for 4-12 wk was as effective as subcutaneous administration in normalizing granule morphology in each of five mice.
Oral administration of bethanechol also caused a significant decrease in spontaneous Con A cap formation in PMN (Table II) PMN were isolated and labeled on monolayers as before (4) . Results are average of three separate determinations using mice of approximately 6 mo of age. The bethanechol-treated mice received the drug ad lib. in the drinking water (400 ;ug/ml) for 10 wk.
mouse cells are attached to a surface, as shown by the low proportion of patched cells in Table II . Second, suspensions of mouse peripheral blood leukocytes contain a much higher proportion of lymphocytes (about 50%) than similar preparations of human blood leukocytes (about 20%). These lymphocytes are rather similar in size to mouse PMN so that differentiation between lymphocytes and PMN in mouse leukocyte preparations by phase contrast microscopy is more difficult than with human leukocyte populations. Most lymphocytes do not adhere to surfaces and so can be conveniently separated from PMN by plating cell suspensions onto glass, followed by vigorous washing to remove nonadherent cells. DISCUSSION CH syndrome in man is a rare autosomal recessive disorder characterized by partial oculocutaneous albinism, photophobia, nystagmus, frequent pyogenic infections, and the presence of giant irregularly shaped lysosomes in most granule containing cells (1, 2, 18 ). Mild to severe peripheral neuropathy has been observed in several CH patients. Febrile episodes are common and an accelerated (lymphoma-like) phase develops, during which patients have hepatosplenomegaly and lymphadenopathy due to lymphoid and hystiocytic infiltrates in these organs (19) . Death usually occurs in childhood, due to infection or hemorrhage (1). A similar disorder has been described in mink (20) , cattle (21) , and mice (3, 22) as well as in cats and in a killer whale (23, 24) . Neutropenia, presumably due to intramedullary destruction of cells (25, 26) is common, and marrow granulocyte responses are decreased (26) . Chemotactic responses of neutrophils from man (27) and mouse (3) are impaired, but particle uptake by CH neutrophils is normal. The complement of lysosomal enzymes is relatively normal (28) although reductions in myeloperoxidase and P-glucuronidase have been reported (29) . These cells exhibit a delay in killing intracellular bacteria (30) , perhaps as a result of a selective degranulation defect which has been detected in leukocytes from CH patients (28) .
In this report, we establish that CH human PMN show the same surface abnormality previously described in the beige (CH) mouse (4) . Exaggerated cap formation by Con A occurred with cells from the first patient who was in the accelerated phase of the disease and was receiving steroid therapy and from the second patient who was not chronically drug treated and whose disease has never progressed to the accelerated stage. Thus, we suppose that spontaneous surface Con A capping is an intrinsic manifestation of CH syndrome and is unrelated to the severity of disease or to steroid therapy.
Con The precise relationship between the surface abnormality (capping) and the granule abnormality in CH syndrome is not known. Since both characteristics respond to cholinergic agents and since the surface abnormality likely reflects a microtubule defect it is tempting to speculate that abnormal microtubule function may also be involved in generation of giant granules. The mechanism by which increased cGMP generation leads to increased microtubule assembly also remains to be established.
It is particularly encouraging that the cholinergic agonists are able to reverse several characteristic abnormalities of CH mice in vivo. Administration of carbachol or bethanechol to CH mice for 3 wk results in the appearance in these animals of a new population of peripheral blood leukocytes in which the granules do not differ from granules in leukocytes from normal mice. Since granule fusion to produce giant lysosomes in PMN occurs during maturation in the bone marrow (33) our results suggest that cholinergic agonists can gain access to this tissue. This is of potential clinical importance since in man the marrow is the site of abnormal granule formation and also of accelerated leukocyte destruction (25) . Con A capping is also reduced to normal levels in PMN from mice treated with cholinergic agonists in vivo, just as previously described in experiments where isolated PMN were exposed to the drugs in vitro (4). It is possible that the therapeutically altered population of PMN may show improved lysosomal degranulation and chemotaxis since colchicine may depress and cGMP and carbachol enhance both these functions in normal PMN (9, 10, 34) .
Each abnormal property of CH mouse or human cells tested thus far, whether in vivo or in vitro, has responded favorably to carbachol and/or bethanechol, although more dramatic responses were consistently observed in mice than in human cells. It is not known, of course, whether these or similar compounds might retard or halt the infiltrative, lymphoma-like phase of the disease that occurs in man. Vincristine has been the mainstay in efforts to control the accelerated phase of the disease (1) . The drug, however, prevents microtubule assembly, and cells from these patients already show evidence of impaired microtubule function. The observations presented here support a rational alternative: treatment of CH syndrome with bethanechol. Prolonged oral administration of bethanechol is not without precedent. Children with familial dysautonomia have been treated with up to 2 mg per Kg daily without serious toxic reactions (35) .
